Table 1 Baseline clinical and tumour characteristics of the study population randomised to receive cTACE or DEB-TACE

From: Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma

 

All patients ( n =177)

cTACE ( n =88)

DEB-TACE ( n =89)

P

Effect size

Clinical characteristics

Age (years)

68.6±8.0

68.3±8.0

68.9±8.0

0.556

0.075

Male gender

135 (76.3%)

69 (78.4%)

66 (74.2%)

0.597

0.079

Viral cirrhosis

130 (73.4%)

68 (76.4%)

62 (70.5%)

0.399

0.127

Alcohol consumption

36 (20.8%)

20 (22.7%)

16 (18.0%)

0.460

0.111

Child-Pugh class A

152 (85.9%)

77 (87.5%)

75 (84.3%)

0.667

0.065

 Class B

25 (14.1%)

11 (12.5%)

14 (15.7%)

—

0.065

ECOG score 0

131 (74.0%)

67 (75.3%)

64 (72.7%)

0.734

0.051

 Score 1

46 (26.0%)

21 (24.3%)

25 (27.3%)

—

0.051

Serum albumin (g l−1)

37.6±5.1

37.6±4.8

37.7±5.5

0.949

0.019

Creatinine (mg dl−1)

0.87±0.21

0.86±0.22

0.88±0.20

0.433

0.095

Total bilirubin (mg dl−1)

1.24±0.67

1.20±0.57

1.28±0.74

0.383

0.121

INR

1.22±0.16

1.22±0.18

1.21±0.13

0.575

0.064

MELD score

9.8±2.4

9.7±2.4

9.8±2.3

0.747

0.043

Segmental injection

122 (68.9%)

60 (68.2%)

62 (69.8%)

0.872

0.024

Tumour burden

Single tumour

84 (47.5%)

39 (44.3%)

45 (50.6%)

0.453

0.113

More than three tumours

21 (11.9%)

11 (12.5%)

10 (11.2%)

0.820

0.034

BCLC stage A

82 (46.3%)

41 (46.6%)

41 (46.1%)

0.876

0.010

 Stage B

49 (27.7%)

23 (26.1%)

26 (29.2%)

—

0.069

 Stage C

46 (26.0%)

24 (27.3%)

22 (24.7%)

—

0.089

Bilobar involvement

37 (20.9%)

20 (22.7%)

17 (19.1%)

0.584

0.082

Diameter of largest tumour (cm)

3.2±1.8

3.4±1.9

3.1±1.6

0.382

0.171

 Median (range)

2.6 (0.9–10)

2.8 (1.0–10)

2.5 (0.9–9)

0.734

0.076

TTV cm3 (median, range)

11.5 (1.0–408)

12.8 (1.0–408)

10.8 (1.0–368)

0.412

0.011

  1. Abbreviations: BCLC=Barcelona Clinic Liver Cancer; cTACE=conventional transarterial chemoembolisation; DEB-TACE=drug-eluting beads transarterial chemoembolisation; ECOG=Eastern Cooperative Oncology Group; INR=international normalized ratio; MELD=model for end-stage liver disease; TTV=total tumour volume.
  2. Effect size <0.1 indicates very small differences; between 0.1 and 0.3 indicates small differences, and >0.3 indicates moderate to large differences; for variables reported in median and range effect size derive from Log10 transformation. No patients belonging to Child-Pugh class C were included in this study.
Back to article page